Annotated Medicine and Device Lists

Lamotrigine

Tablet 50 mg Tablet 100 mg Tablet 25 mg Tablet 200 mg Tablet (buffered chewable, dispersible) 2 mg Tablet (buffered chewable, dispersible) 5 mg Tablet (buffered chewable, dispersible) 25 mg Tablet (buffered chewable, dispersible) 50 mg Tablet (buffered chewable, dispersible) 100 mg Tablet (buffered chewable, dispersible) 200 mg

This medicine is present in:

List	Section	Observation
Peru	05. Anticonvulsants/Antiepileptics	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Cuba	05. ANTICONVULSIVOS	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

This medicine is present in:

List	Section	Observation
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

Information Resources: Lamotrigine

No information available